Pharmala Biotech Holdings Inc. (CSE:MDMA)
0.1600
+0.0050 (3.23%)
Jul 21, 2026, 12:51 PM EST
Pharmala Biotech Holdings Revenue
Pharmala Biotech Holdings had revenue of 280.58K CAD in the quarter ending February 28, 2026, with 92.63% growth. This brings the company's revenue in the last twelve months to 889.57K, up 106.79% year-over-year. In the fiscal year ending August 31, 2025, Pharmala Biotech Holdings had annual revenue of 605.50K, down -41.51%.
Revenue (ttm)
889.57K
Revenue Growth
+106.79%
P/S Ratio
18.97
Revenue / Employee
n/a
Employees
n/a
Market Cap
16.88M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 605.50K | -429.80K | -41.51% |
| Aug 31, 2024 | 1.04M | 503.29K | 94.60% |
| Aug 31, 2023 | 532.00K | 453.93K | 581.44% |
| Aug 31, 2022 | 78.07K | - | - |
| Aug 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionPharmala Biotech Holdings News
- 7 hours ago - PharmAla enters up to $100M ALA-002 license pact with Jupiter Neurosciences - TheFly
- 7 hours ago - PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 - GlobeNewsWire
- 15 days ago - PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset - GlobeNewsWire
- 2 months ago - PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million - GlobeNewsWire
- 2 months ago - PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01 - GlobeNewsWire
- 3 months ago - PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01 - GlobeNewsWire
- 3 months ago - PharmAla Issues Q2 Financial Statements and Grants Options - GlobeNewsWire
- 3 months ago - Pharmala Biotech Holdings Earnings release: Q2 2026 - Filings